Literature DB >> 23416221

Model for end-stage liver disease-based organ allocation: managing the exceptions to the rules.

David S Goldberg, Michael B Fallon.   

Abstract

Entities:  

Mesh：

Year:  2013        PMID： 23416221      PMCID： PMC5976500          DOI： 10.1016/j.cgh.2013.02.014

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN： 1542-3565            Impact factor:   11.382


× No keyword cloud information.
  20 in total

1.  Prospective evaluation of outcomes and predictors of mortality in patients with hepatopulmonary syndrome undergoing liver transplantation.

Authors:  Miguel R Arguedas; Gary A Abrams; Michael J Krowka; Michael B Fallon
Journal:  Hepatology       Date:  2003-01       Impact factor: 17.425

2.  Priority of candidates with hepatocellular carcinoma awaiting liver transplantation can be reduced after successful bridge therapy.

Authors:  Alessandro Cucchetti; Matteo Cescon; Eleonora Bigonzi; Fabio Piscaglia; Rita Golfieri; Giorgio Ercolani; Maria Cristina Morelli; Matteo Ravaioli; Antonio Daniele Pinna
Journal:  Liver Transpl       Date:  2011-11       Impact factor: 5.799

3.  Increasing disparity in waitlist mortality rates with increased model for end-stage liver disease scores for candidates with hepatocellular carcinoma versus candidates without hepatocellular carcinoma.

Authors:  David Goldberg; Benjamin French; Peter Abt; Sandy Feng; Andrew M Cameron
Journal:  Liver Transpl       Date:  2012-04       Impact factor: 5.799

4.  Model for end-stage liver disease (MELD) exception for bacterial cholangitis.

Authors:  Gregory J Gores; Robert G Gish; Roshan Shrestha; Russell H Wiesner
Journal:  Liver Transpl       Date:  2006-12       Impact factor: 5.799

5.  Hepatocellular carcinoma patients are advantaged in the current liver transplant allocation system.

Authors:  K Washburn; E Edwards; A Harper; R Freeman
Journal:  Am J Transplant       Date:  2010-05-10       Impact factor: 8.086

6.  Liver transplantation in the United States, 1999-2008.

Authors:  P J Thuluvath; M K Guidinger; J J Fung; L B Johnson; S C Rayhill; S J Pelletier
Journal:  Am J Transplant       Date:  2010-04       Impact factor: 8.086

7.  Exception point applications for 15 points: an unintended consequence of the share 15 policy.

Authors:  Therese Bittermann; George Makar; David Goldberg
Journal:  Liver Transpl       Date:  2012-10-10       Impact factor: 5.799

8.  Natural history of hepatopulmonary syndrome: Impact of liver transplantation.

Authors:  Karen L Swanson; Russell H Wiesner; Michael J Krowka
Journal:  Hepatology       Date:  2005-05       Impact factor: 17.425

Review 9.  A model to predict survival in patients with end-stage liver disease.

Authors:  P S Kamath; R H Wiesner; M Malinchoc; W Kremers; T M Therneau; C L Kosberg; G D'Amico; E R Dickson; W R Kim
Journal:  Hepatology       Date:  2001-02       Impact factor: 17.425

10.  Prognostic significance of the hepatopulmonary syndrome in patients with cirrhosis.

Authors:  Peter Schenk; Maximilian Schöniger-Hekele; Valentin Fuhrmann; Christian Madl; Gerd Silberhumer; Christian Müller
Journal:  Gastroenterology       Date:  2003-10       Impact factor: 22.682
View more
  4 in total

Review 1.  Treatment Barriers in Portopulmonary Hypertension.

Authors:  Batool AbuHalimeh; Michael J Krowka; Adriano R Tonelli
Journal:  Hepatology       Date:  2018-12-18       Impact factor: 17.425

2.  TNF-α suppression by glutathione preconditioning attenuates hepatic ischemia reperfusion injury in young and aged rats.

Authors:  Arumugam Suyavaran; Chitteti Ramamurthy; Ramachandran Mareeswaran; Ariraman Subastri; Polaki Lokeswara Rao; Chinnasamy Thirunavukkarasu
Journal:  Inflamm Res       Date:  2014-11-25       Impact factor: 4.575

3.  Variable Use of Model for End-Stage Liver Disease Exception Points in Patients With Neuroendocrine Tumors Metastatic to the Liver and Its Impact on Patient Outcomes.

Authors:  Yael R Nobel; David S Goldberg
Journal:  Transplantation       Date:  2015-11       Impact factor: 4.939

Review 4.  Liver Transplantation for Cholestatic Liver Diseases in Adults.

Authors:  Vandana Khungar; David Seth Goldberg
Journal:  Clin Liver Dis       Date:  2015-10-23       Impact factor: 6.126
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.